The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).
 
Ryan Phillips
No Relationships to Disclose
 
Noura Radwan
No Relationships to Disclose
 
Ashley Ross
No Relationships to Disclose
 
Steven P. Rowe
No Relationships to Disclose
 
Michael A. Gorin
No Relationships to Disclose
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Curtiland Deville
No Relationships to Disclose
 
Stephen C Greco
No Relationships to Disclose
 
Samuel R. Denmeade
No Relationships to Disclose
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon
Research Funding - Lilly (Inst)
 
Daniel Y. Song
No Relationships to Disclose
 
Maximilian Diehn
Stock and Other Ownership Interests - CAPP Medical; CiberMed; Quanticel Pharma
Consulting or Advisory Role - Quanticel Pharma; Roche
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection assigned to Stanford University (Inst); Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst)
Travel, Accommodations, Expenses - Roche; Varian Medical Systems
 
Hao Wang
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Astellas Pharma; Churchill Pharmaceuticals; Medivation; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); pfizer (Inst)
 
Kenneth J. Pienta
Leadership - Curis
Honoraria - Johnson & Johnson
Research Funding - Celsee Diagnostics; Johnson & Johnson (Inst)
 
Martin G. Pomper
Leadership - Cancer Targeting Systems
Stock and Other Ownership Interests - Cancer Targeting Systems
Consulting or Advisory Role - Cancer Targeting Systems
Research Funding - Cancer Targeting Systems (Inst); Juno Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to Cancer Targeting Systems, Progenics Phama and Advanced Accelerator Applications (Inst)
 
Theodore L. DeWeese
No Relationships to Disclose
 
Adam P. Dicker
No Relationships to Disclose
 
Mario A. Eisenberger
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi
 
Phuoc T. Tran
Consulting or Advisory Role - Astellas Pharma; GenomeDx; Regeneron
Research Funding - Astellas Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.